nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—FLT4—polycystic ovary syndrome	0.651	1	CbGaD
Sorafenib—Regorafenib—FLT4—polycystic ovary syndrome	0.00582	1	CrCbGaD
Sorafenib—Gastrointestinal symptom NOS—Metformin—polycystic ovary syndrome	0.00189	0.0643	CcSEcCtD
Sorafenib—Respiratory distress—Metformin—polycystic ovary syndrome	0.00175	0.0595	CcSEcCtD
Sorafenib—CDKL3—endocrine gland—polycystic ovary syndrome	0.00155	0.0121	CbGeAlD
Sorafenib—CDKL2—endocrine gland—polycystic ovary syndrome	0.00142	0.0111	CbGeAlD
Sorafenib—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.00137	0.0467	CcSEcCtD
Sorafenib—MAPK15—endocrine gland—polycystic ovary syndrome	0.00128	0.00999	CbGeAlD
Sorafenib—CYP2C19—urine—polycystic ovary syndrome	0.00111	0.00865	CbGeAlD
Sorafenib—Neuropathy—Metformin—polycystic ovary syndrome	0.00104	0.0355	CcSEcCtD
Sorafenib—CDK7—uterus—polycystic ovary syndrome	0.000982	0.00767	CbGeAlD
Sorafenib—MAPK11—adipose tissue—polycystic ovary syndrome	0.000976	0.00762	CbGeAlD
Sorafenib—CDK7—adipose tissue—polycystic ovary syndrome	0.00096	0.0075	CbGeAlD
Sorafenib—TAOK2—pituitary gland—polycystic ovary syndrome	0.000957	0.00747	CbGeAlD
Sorafenib—TAOK2—adipose tissue—polycystic ovary syndrome	0.000953	0.00744	CbGeAlD
Sorafenib—FLT4—embryo—polycystic ovary syndrome	0.000951	0.00743	CbGeAlD
Sorafenib—TIE1—adrenal cortex—polycystic ovary syndrome	0.000943	0.00736	CbGeAlD
Sorafenib—ZAK—endometrium—polycystic ovary syndrome	0.000921	0.00719	CbGeAlD
Sorafenib—CYP1A2—urine—polycystic ovary syndrome	0.000905	0.00707	CbGeAlD
Sorafenib—HIPK3—endometrium—polycystic ovary syndrome	0.000901	0.00704	CbGeAlD
Sorafenib—MAPK11—adrenal gland—polycystic ovary syndrome	0.000876	0.00684	CbGeAlD
Sorafenib—EPHX2—adrenal cortex—polycystic ovary syndrome	0.000864	0.00675	CbGeAlD
Sorafenib—HIPK4—endocrine gland—polycystic ovary syndrome	0.000862	0.00673	CbGeAlD
Sorafenib—CDK7—adrenal gland—polycystic ovary syndrome	0.000861	0.00672	CbGeAlD
Sorafenib—CYP2C9—urine—polycystic ovary syndrome	0.000859	0.00671	CbGeAlD
Sorafenib—TAOK2—adrenal gland—polycystic ovary syndrome	0.000855	0.00667	CbGeAlD
Sorafenib—ZAK—uterus—polycystic ovary syndrome	0.000849	0.00662	CbGeAlD
Sorafenib—AURKC—adrenal gland—polycystic ovary syndrome	0.000848	0.00662	CbGeAlD
Sorafenib—RET—embryo—polycystic ovary syndrome	0.00084	0.00656	CbGeAlD
Sorafenib—ZAK—adipose tissue—polycystic ovary syndrome	0.00083	0.00648	CbGeAlD
Sorafenib—MAPK11—female gonad—polycystic ovary syndrome	0.000816	0.00637	CbGeAlD
Sorafenib—HIPK3—pituitary gland—polycystic ovary syndrome	0.000816	0.00637	CbGeAlD
Sorafenib—HIPK3—adipose tissue—polycystic ovary syndrome	0.000812	0.00634	CbGeAlD
Sorafenib—BRAF—endometrium—polycystic ovary syndrome	0.000808	0.0063	CbGeAlD
Sorafenib—Pain in extremity—Metformin—polycystic ovary syndrome	0.000805	0.0274	CcSEcCtD
Sorafenib—CDK7—female gonad—polycystic ovary syndrome	0.000803	0.00627	CbGeAlD
Sorafenib—TAOK2—female gonad—polycystic ovary syndrome	0.000797	0.00622	CbGeAlD
Sorafenib—TAOK2—vagina—polycystic ovary syndrome	0.000792	0.00618	CbGeAlD
Sorafenib—FLT4—adrenal cortex—polycystic ovary syndrome	0.000779	0.00608	CbGeAlD
Sorafenib—TIE1—uterus—polycystic ovary syndrome	0.000776	0.00606	CbGeAlD
Sorafenib—TIE1—adipose tissue—polycystic ovary syndrome	0.000759	0.00593	CbGeAlD
Sorafenib—Dehydration—Metformin—polycystic ovary syndrome	0.000748	0.0255	CcSEcCtD
Sorafenib—CDK7—endocrine gland—polycystic ovary syndrome	0.000747	0.00583	CbGeAlD
Sorafenib—ZAK—adrenal gland—polycystic ovary syndrome	0.000744	0.00581	CbGeAlD
Sorafenib—BRAF—uterus—polycystic ovary syndrome	0.000744	0.00581	CbGeAlD
Sorafenib—FLT1—embryo—polycystic ovary syndrome	0.00074	0.00577	CbGeAlD
Sorafenib—AURKC—endocrine gland—polycystic ovary syndrome	0.000735	0.00574	CbGeAlD
Sorafenib—RAF1—embryo—polycystic ovary syndrome	0.000735	0.00574	CbGeAlD
Sorafenib—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.000735	0.0251	CcSEcCtD
Sorafenib—BRAF—pituitary gland—polycystic ovary syndrome	0.000731	0.0057	CbGeAlD
Sorafenib—HIPK3—adrenal gland—polycystic ovary syndrome	0.000729	0.00569	CbGeAlD
Sorafenib—MAP3K7—adrenal cortex—polycystic ovary syndrome	0.000728	0.00568	CbGeAlD
Sorafenib—BRAF—adipose tissue—polycystic ovary syndrome	0.000728	0.00568	CbGeAlD
Sorafenib—Breast disorder—Metformin—polycystic ovary syndrome	0.000727	0.0248	CcSEcCtD
Sorafenib—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00072	0.0245	CcSEcCtD
Sorafenib—EPHX2—uterus—polycystic ovary syndrome	0.000711	0.00555	CbGeAlD
Sorafenib—MKNK2—adrenal cortex—polycystic ovary syndrome	0.000706	0.00551	CbGeAlD
Sorafenib—EPHX2—pituitary gland—polycystic ovary syndrome	0.000698	0.00545	CbGeAlD
Sorafenib—MKNK1—adrenal cortex—polycystic ovary syndrome	0.000697	0.00544	CbGeAlD
Sorafenib—EPHX2—adipose tissue—polycystic ovary syndrome	0.000696	0.00543	CbGeAlD
Sorafenib—ZAK—female gonad—polycystic ovary syndrome	0.000694	0.00542	CbGeAlD
Sorafenib—PDGFRA—embryo—polycystic ovary syndrome	0.000693	0.00541	CbGeAlD
Sorafenib—ZAK—vagina—polycystic ovary syndrome	0.00069	0.00539	CbGeAlD
Sorafenib—Pancreatitis—Metformin—polycystic ovary syndrome	0.000682	0.0232	CcSEcCtD
Sorafenib—EPHA6—endocrine gland—polycystic ovary syndrome	0.000681	0.00532	CbGeAlD
Sorafenib—TIE1—adrenal gland—polycystic ovary syndrome	0.000681	0.00532	CbGeAlD
Sorafenib—HIPK3—female gonad—polycystic ovary syndrome	0.000679	0.0053	CbGeAlD
Sorafenib—HIPK3—vagina—polycystic ovary syndrome	0.000675	0.00527	CbGeAlD
Sorafenib—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.000667	0.0227	CcSEcCtD
Sorafenib—CYP3A4—urine—polycystic ovary syndrome	0.000655	0.00512	CbGeAlD
Sorafenib—BRAF—adrenal gland—polycystic ovary syndrome	0.000653	0.0051	CbGeAlD
Sorafenib—Neutropenia—Metformin—polycystic ovary syndrome	0.00065	0.0222	CcSEcCtD
Sorafenib—MAP3K7—endometrium—polycystic ovary syndrome	0.00065	0.00507	CbGeAlD
Sorafenib—ZAK—endocrine gland—polycystic ovary syndrome	0.000646	0.00504	CbGeAlD
Sorafenib—CYP2D6—urine—polycystic ovary syndrome	0.000645	0.00503	CbGeAlD
Sorafenib—RALBP1—adrenal cortex—polycystic ovary syndrome	0.000637	0.00497	CbGeAlD
Sorafenib—TIE1—female gonad—polycystic ovary syndrome	0.000635	0.00496	CbGeAlD
Sorafenib—FGFR1—uterus—polycystic ovary syndrome	0.000633	0.00494	CbGeAlD
Sorafenib—HIPK3—endocrine gland—polycystic ovary syndrome	0.000632	0.00493	CbGeAlD
Sorafenib—MKNK2—endometrium—polycystic ovary syndrome	0.00063	0.00492	CbGeAlD
Sorafenib—FLT4—adipose tissue—polycystic ovary syndrome	0.000627	0.0049	CbGeAlD
Sorafenib—KDR—embryo—polycystic ovary syndrome	0.000625	0.00488	CbGeAlD
Sorafenib—EPHX2—adrenal gland—polycystic ovary syndrome	0.000624	0.00487	CbGeAlD
Sorafenib—MKNK1—endometrium—polycystic ovary syndrome	0.000622	0.00486	CbGeAlD
Sorafenib—FGFR1—pituitary gland—polycystic ovary syndrome	0.000621	0.00485	CbGeAlD
Sorafenib—Infestation—Metformin—polycystic ovary syndrome	0.00062	0.0211	CcSEcCtD
Sorafenib—Infestation NOS—Metformin—polycystic ovary syndrome	0.00062	0.0211	CcSEcCtD
Sorafenib—FLT3—adrenal gland—polycystic ovary syndrome	0.000619	0.00484	CbGeAlD
Sorafenib—FGFR1—adipose tissue—polycystic ovary syndrome	0.000619	0.00483	CbGeAlD
Sorafenib—CSF1R—embryo—polycystic ovary syndrome	0.00061	0.00476	CbGeAlD
Sorafenib—BRAF—female gonad—polycystic ovary syndrome	0.000609	0.00475	CbGeAlD
Sorafenib—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.000608	0.0207	CcSEcCtD
Sorafenib—FLT1—adrenal cortex—polycystic ovary syndrome	0.000606	0.00473	CbGeAlD
Sorafenib—BRAF—vagina—polycystic ovary syndrome	0.000605	0.00472	CbGeAlD
Sorafenib—RAF1—adrenal cortex—polycystic ovary syndrome	0.000603	0.0047	CbGeAlD
Sorafenib—MAP3K7—uterus—polycystic ovary syndrome	0.000599	0.00468	CbGeAlD
Sorafenib—MAP3K7—pituitary gland—polycystic ovary syndrome	0.000588	0.00459	CbGeAlD
Sorafenib—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000587	0.02	CcSEcCtD
Sorafenib—MAP3K7—adipose tissue—polycystic ovary syndrome	0.000586	0.00457	CbGeAlD
Sorafenib—EPHX2—female gonad—polycystic ovary syndrome	0.000582	0.00454	CbGeAlD
Sorafenib—MKNK2—uterus—polycystic ovary syndrome	0.000581	0.00453	CbGeAlD
Sorafenib—EPHX2—vagina—polycystic ovary syndrome	0.000578	0.00451	CbGeAlD
Sorafenib—FLT3—female gonad—polycystic ovary syndrome	0.000578	0.00451	CbGeAlD
Sorafenib—MKNK2—pituitary gland—polycystic ovary syndrome	0.00057	0.00445	CbGeAlD
Sorafenib—RALBP1—endometrium—polycystic ovary syndrome	0.000569	0.00444	CbGeAlD
Sorafenib—MKNK2—adipose tissue—polycystic ovary syndrome	0.000568	0.00443	CbGeAlD
Sorafenib—MKNK1—pituitary gland—polycystic ovary syndrome	0.000563	0.00439	CbGeAlD
Sorafenib—FLT4—adrenal gland—polycystic ovary syndrome	0.000563	0.00439	CbGeAlD
Sorafenib—MKNK1—adipose tissue—polycystic ovary syndrome	0.000561	0.00438	CbGeAlD
Sorafenib—RET—pituitary gland—polycystic ovary syndrome	0.000556	0.00434	CbGeAlD
Sorafenib—FGFR1—adrenal gland—polycystic ovary syndrome	0.000555	0.00433	CbGeAlD
Sorafenib—KIT—embryo—polycystic ovary syndrome	0.000554	0.00432	CbGeAlD
Sorafenib—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000547	0.0187	CcSEcCtD
Sorafenib—FLT1—endometrium—polycystic ovary syndrome	0.000541	0.00422	CbGeAlD
Sorafenib—PDGFRB—embryo—polycystic ovary syndrome	0.000541	0.00422	CbGeAlD
Sorafenib—RAF1—endometrium—polycystic ovary syndrome	0.000538	0.0042	CbGeAlD
Sorafenib—FLT3—endocrine gland—polycystic ovary syndrome	0.000537	0.00419	CbGeAlD
Sorafenib—EPHB6—endometrium—polycystic ovary syndrome	0.000535	0.00418	CbGeAlD
Sorafenib—MAP3K7—adrenal gland—polycystic ovary syndrome	0.000526	0.0041	CbGeAlD
Sorafenib—FLT4—female gonad—polycystic ovary syndrome	0.000525	0.0041	CbGeAlD
Sorafenib—RALBP1—uterus—polycystic ovary syndrome	0.000524	0.00409	CbGeAlD
Sorafenib—FGFR1—female gonad—polycystic ovary syndrome	0.000518	0.00404	CbGeAlD
Sorafenib—Flushing—Metformin—polycystic ovary syndrome	0.000517	0.0176	CcSEcCtD
Sorafenib—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000517	0.0176	CcSEcCtD
Sorafenib—RALBP1—pituitary gland—polycystic ovary syndrome	0.000515	0.00402	CbGeAlD
Sorafenib—FGFR1—vagina—polycystic ovary syndrome	0.000514	0.00402	CbGeAlD
Sorafenib—RALBP1—adipose tissue—polycystic ovary syndrome	0.000513	0.004	CbGeAlD
Sorafenib—MAP2K5—adrenal cortex—polycystic ovary syndrome	0.000512	0.004	CbGeAlD
Sorafenib—KDR—adrenal cortex—polycystic ovary syndrome	0.000512	0.004	CbGeAlD
Sorafenib—MKNK2—adrenal gland—polycystic ovary syndrome	0.000509	0.00398	CbGeAlD
Sorafenib—Angiopathy—Metformin—polycystic ovary syndrome	0.000505	0.0172	CcSEcCtD
Sorafenib—Immune system disorder—Metformin—polycystic ovary syndrome	0.000503	0.0171	CcSEcCtD
Sorafenib—MKNK1—adrenal gland—polycystic ovary syndrome	0.000503	0.00393	CbGeAlD
Sorafenib—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000502	0.0171	CcSEcCtD
Sorafenib—CSF1R—adrenal cortex—polycystic ovary syndrome	0.0005	0.0039	CbGeAlD
Sorafenib—FLT1—uterus—polycystic ovary syndrome	0.000499	0.00389	CbGeAlD
Sorafenib—RET—adrenal gland—polycystic ovary syndrome	0.000497	0.00388	CbGeAlD
Sorafenib—RAF1—uterus—polycystic ovary syndrome	0.000496	0.00387	CbGeAlD
Sorafenib—UGT1A9—endocrine gland—polycystic ovary syndrome	0.000495	0.00386	CbGeAlD
Sorafenib—MAP3K7—female gonad—polycystic ovary syndrome	0.00049	0.00383	CbGeAlD
Sorafenib—FLT1—pituitary gland—polycystic ovary syndrome	0.00049	0.00382	CbGeAlD
Sorafenib—FLT4—endocrine gland—polycystic ovary syndrome	0.000488	0.00381	CbGeAlD
Sorafenib—FLT1—adipose tissue—polycystic ovary syndrome	0.000488	0.00381	CbGeAlD
Sorafenib—MAP3K7—vagina—polycystic ovary syndrome	0.000487	0.0038	CbGeAlD
Sorafenib—RAF1—pituitary gland—polycystic ovary syndrome	0.000487	0.0038	CbGeAlD
Sorafenib—RAF1—adipose tissue—polycystic ovary syndrome	0.000485	0.00379	CbGeAlD
Sorafenib—Malnutrition—Metformin—polycystic ovary syndrome	0.000485	0.0165	CcSEcCtD
Sorafenib—Erythema—Metformin—polycystic ovary syndrome	0.000485	0.0165	CcSEcCtD
Sorafenib—EPHB6—pituitary gland—polycystic ovary syndrome	0.000484	0.00378	CbGeAlD
Sorafenib—EPHB6—adipose tissue—polycystic ovary syndrome	0.000482	0.00376	CbGeAlD
Sorafenib—MKNK2—female gonad—polycystic ovary syndrome	0.000475	0.00371	CbGeAlD
Sorafenib—Dysgeusia—Metformin—polycystic ovary syndrome	0.000475	0.0162	CcSEcCtD
Sorafenib—STK10—uterus—polycystic ovary syndrome	0.000472	0.00369	CbGeAlD
Sorafenib—MKNK2—vagina—polycystic ovary syndrome	0.000472	0.00368	CbGeAlD
Sorafenib—MKNK1—female gonad—polycystic ovary syndrome	0.000469	0.00366	CbGeAlD
Sorafenib—PDGFRA—uterus—polycystic ovary syndrome	0.000467	0.00365	CbGeAlD
Sorafenib—MKNK1—vagina—polycystic ovary syndrome	0.000466	0.00364	CbGeAlD
Sorafenib—Muscle spasms—Metformin—polycystic ovary syndrome	0.000466	0.0159	CcSEcCtD
Sorafenib—STK10—adipose tissue—polycystic ovary syndrome	0.000462	0.0036	CbGeAlD
Sorafenib—RALBP1—adrenal gland—polycystic ovary syndrome	0.00046	0.00359	CbGeAlD
Sorafenib—MAP2K5—endometrium—polycystic ovary syndrome	0.000457	0.00357	CbGeAlD
Sorafenib—KDR—endometrium—polycystic ovary syndrome	0.000457	0.00357	CbGeAlD
Sorafenib—PDGFRA—adipose tissue—polycystic ovary syndrome	0.000457	0.00357	CbGeAlD
Sorafenib—CSF1R—endometrium—polycystic ovary syndrome	0.000446	0.00349	CbGeAlD
Sorafenib—PDGFRB—adrenal cortex—polycystic ovary syndrome	0.000443	0.00346	CbGeAlD
Sorafenib—MKNK2—endocrine gland—polycystic ovary syndrome	0.000442	0.00345	CbGeAlD
Sorafenib—FLT1—adrenal gland—polycystic ovary syndrome	0.000437	0.00342	CbGeAlD
Sorafenib—MKNK1—endocrine gland—polycystic ovary syndrome	0.000436	0.0034	CbGeAlD
Sorafenib—RAF1—adrenal gland—polycystic ovary syndrome	0.000435	0.0034	CbGeAlD
Sorafenib—Syncope—Metformin—polycystic ovary syndrome	0.000435	0.0148	CcSEcCtD
Sorafenib—EPHB6—adrenal gland—polycystic ovary syndrome	0.000432	0.00338	CbGeAlD
Sorafenib—RET—endocrine gland—polycystic ovary syndrome	0.000431	0.00336	CbGeAlD
Sorafenib—RALBP1—female gonad—polycystic ovary syndrome	0.000429	0.00335	CbGeAlD
Sorafenib—RALBP1—vagina—polycystic ovary syndrome	0.000426	0.00333	CbGeAlD
Sorafenib—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000426	0.0145	CcSEcCtD
Sorafenib—KDR—uterus—polycystic ovary syndrome	0.000422	0.00329	CbGeAlD
Sorafenib—Hypertension—Metformin—polycystic ovary syndrome	0.000418	0.0143	CcSEcCtD
Sorafenib—STK10—adrenal gland—polycystic ovary syndrome	0.000414	0.00323	CbGeAlD
Sorafenib—MAP2K5—pituitary gland—polycystic ovary syndrome	0.000414	0.00323	CbGeAlD
Sorafenib—KDR—pituitary gland—polycystic ovary syndrome	0.000414	0.00323	CbGeAlD
Sorafenib—Myalgia—Metformin—polycystic ovary syndrome	0.000413	0.0141	CcSEcCtD
Sorafenib—MAP2K5—adipose tissue—polycystic ovary syndrome	0.000412	0.00322	CbGeAlD
Sorafenib—KDR—adipose tissue—polycystic ovary syndrome	0.000412	0.00322	CbGeAlD
Sorafenib—CYP3A7—endocrine gland—polycystic ovary syndrome	0.000411	0.00321	CbGeAlD
Sorafenib—CSF1R—uterus—polycystic ovary syndrome	0.000411	0.00321	CbGeAlD
Sorafenib—PDGFRA—adrenal gland—polycystic ovary syndrome	0.00041	0.0032	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00041	0.014	CcSEcCtD
Sorafenib—FLT1—female gonad—polycystic ovary syndrome	0.000408	0.00318	CbGeAlD
Sorafenib—RAF1—female gonad—polycystic ovary syndrome	0.000406	0.00317	CbGeAlD
Sorafenib—FLT1—vagina—polycystic ovary syndrome	0.000405	0.00317	CbGeAlD
Sorafenib—KIT—endometrium—polycystic ovary syndrome	0.000405	0.00316	CbGeAlD
Sorafenib—CSF1R—pituitary gland—polycystic ovary syndrome	0.000404	0.00315	CbGeAlD
Sorafenib—EPHB6—female gonad—polycystic ovary syndrome	0.000403	0.00315	CbGeAlD
Sorafenib—RAF1—vagina—polycystic ovary syndrome	0.000403	0.00315	CbGeAlD
Sorafenib—CSF1R—adipose tissue—polycystic ovary syndrome	0.000402	0.00314	CbGeAlD
Sorafenib—EPHB6—vagina—polycystic ovary syndrome	0.000401	0.00313	CbGeAlD
Sorafenib—RALBP1—endocrine gland—polycystic ovary syndrome	0.000399	0.00311	CbGeAlD
Sorafenib—PDGFRB—endometrium—polycystic ovary syndrome	0.000396	0.00309	CbGeAlD
Sorafenib—Infection—Metformin—polycystic ovary syndrome	0.000393	0.0134	CcSEcCtD
Sorafenib—Shock—Metformin—polycystic ovary syndrome	0.000389	0.0133	CcSEcCtD
Sorafenib—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000388	0.0132	CcSEcCtD
Sorafenib—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000387	0.0132	CcSEcCtD
Sorafenib—STK10—female gonad—polycystic ovary syndrome	0.000386	0.00301	CbGeAlD
Sorafenib—Skin disorder—Metformin—polycystic ovary syndrome	0.000384	0.0131	CcSEcCtD
Sorafenib—STK10—vagina—polycystic ovary syndrome	0.000384	0.003	CbGeAlD
Sorafenib—PDGFRA—female gonad—polycystic ovary syndrome	0.000382	0.00298	CbGeAlD
Sorafenib—PDGFRA—vagina—polycystic ovary syndrome	0.00038	0.00297	CbGeAlD
Sorafenib—FLT1—endocrine gland—polycystic ovary syndrome	0.000379	0.00296	CbGeAlD
Sorafenib—RAF1—endocrine gland—polycystic ovary syndrome	0.000377	0.00294	CbGeAlD
Sorafenib—Anorexia—Metformin—polycystic ovary syndrome	0.000377	0.0129	CcSEcCtD
Sorafenib—KIT—uterus—polycystic ovary syndrome	0.000374	0.00292	CbGeAlD
Sorafenib—MAP2K5—adrenal gland—polycystic ovary syndrome	0.00037	0.00289	CbGeAlD
Sorafenib—KDR—adrenal gland—polycystic ovary syndrome	0.00037	0.00289	CbGeAlD
Sorafenib—KIT—pituitary gland—polycystic ovary syndrome	0.000367	0.00286	CbGeAlD
Sorafenib—KIT—adipose tissue—polycystic ovary syndrome	0.000365	0.00285	CbGeAlD
Sorafenib—PDGFRB—uterus—polycystic ovary syndrome	0.000365	0.00285	CbGeAlD
Sorafenib—CSF1R—adrenal gland—polycystic ovary syndrome	0.000361	0.00282	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00036	0.0123	CcSEcCtD
Sorafenib—STK10—endocrine gland—polycystic ovary syndrome	0.000359	0.0028	CbGeAlD
Sorafenib—PDGFRB—pituitary gland—polycystic ovary syndrome	0.000358	0.0028	CbGeAlD
Sorafenib—PDGFRB—adipose tissue—polycystic ovary syndrome	0.000357	0.00279	CbGeAlD
Sorafenib—PDGFRA—endocrine gland—polycystic ovary syndrome	0.000355	0.00278	CbGeAlD
Sorafenib—Dyspnoea—Metformin—polycystic ovary syndrome	0.000353	0.012	CcSEcCtD
Sorafenib—HTR2B—adrenal cortex—polycystic ovary syndrome	0.000351	0.00274	CbGeAlD
Sorafenib—Dyspepsia—Metformin—polycystic ovary syndrome	0.000348	0.0119	CcSEcCtD
Sorafenib—KDR—female gonad—polycystic ovary syndrome	0.000345	0.00269	CbGeAlD
Sorafenib—MAP2K5—female gonad—polycystic ovary syndrome	0.000345	0.00269	CbGeAlD
Sorafenib—Decreased appetite—Metformin—polycystic ovary syndrome	0.000344	0.0117	CcSEcCtD
Sorafenib—KDR—vagina—polycystic ovary syndrome	0.000343	0.00268	CbGeAlD
Sorafenib—MAP2K5—vagina—polycystic ovary syndrome	0.000343	0.00268	CbGeAlD
Sorafenib—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000342	0.0116	CcSEcCtD
Sorafenib—Fatigue—Metformin—polycystic ovary syndrome	0.000341	0.0116	CcSEcCtD
Sorafenib—UGT1A1—endocrine gland—polycystic ovary syndrome	0.000339	0.00265	CbGeAlD
Sorafenib—Constipation—Metformin—polycystic ovary syndrome	0.000338	0.0115	CcSEcCtD
Sorafenib—CSF1R—female gonad—polycystic ovary syndrome	0.000337	0.00263	CbGeAlD
Sorafenib—CSF1R—vagina—polycystic ovary syndrome	0.000334	0.00261	CbGeAlD
Sorafenib—KIT—adrenal gland—polycystic ovary syndrome	0.000328	0.00256	CbGeAlD
Sorafenib—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000323	0.011	CcSEcCtD
Sorafenib—MAP2K5—endocrine gland—polycystic ovary syndrome	0.000321	0.0025	CbGeAlD
Sorafenib—KDR—endocrine gland—polycystic ovary syndrome	0.000321	0.0025	CbGeAlD
Sorafenib—PDGFRB—adrenal gland—polycystic ovary syndrome	0.00032	0.0025	CbGeAlD
Sorafenib—Urticaria—Metformin—polycystic ovary syndrome	0.000314	0.0107	CcSEcCtD
Sorafenib—HTR2B—endometrium—polycystic ovary syndrome	0.000314	0.00245	CbGeAlD
Sorafenib—CSF1R—endocrine gland—polycystic ovary syndrome	0.000313	0.00244	CbGeAlD
Sorafenib—Abdominal pain—Metformin—polycystic ovary syndrome	0.000313	0.0107	CcSEcCtD
Sorafenib—KIT—female gonad—polycystic ovary syndrome	0.000306	0.00239	CbGeAlD
Sorafenib—KIT—vagina—polycystic ovary syndrome	0.000304	0.00237	CbGeAlD
Sorafenib—PDGFRB—female gonad—polycystic ovary syndrome	0.000298	0.00233	CbGeAlD
Sorafenib—PDGFRB—vagina—polycystic ovary syndrome	0.000297	0.00232	CbGeAlD
Sorafenib—ABCC4—uterus—polycystic ovary syndrome	0.000291	0.00227	CbGeAlD
Sorafenib—HTR2B—uterus—polycystic ovary syndrome	0.000289	0.00226	CbGeAlD
Sorafenib—KIT—endocrine gland—polycystic ovary syndrome	0.000284	0.00222	CbGeAlD
Sorafenib—ABCC4—adipose tissue—polycystic ovary syndrome	0.000284	0.00222	CbGeAlD
Sorafenib—Asthenia—Metformin—polycystic ovary syndrome	0.000284	0.00968	CcSEcCtD
Sorafenib—HTR2B—adipose tissue—polycystic ovary syndrome	0.000283	0.00221	CbGeAlD
Sorafenib—Pruritus—Metformin—polycystic ovary syndrome	0.00028	0.00954	CcSEcCtD
Sorafenib—PDGFRB—endocrine gland—polycystic ovary syndrome	0.000278	0.00217	CbGeAlD
Sorafenib—Diarrhoea—Metformin—polycystic ovary syndrome	0.000271	0.00923	CcSEcCtD
Sorafenib—Dizziness—Metformin—polycystic ovary syndrome	0.000262	0.00892	CcSEcCtD
Sorafenib—ABCC4—adrenal gland—polycystic ovary syndrome	0.000255	0.00199	CbGeAlD
Sorafenib—HTR2B—adrenal gland—polycystic ovary syndrome	0.000254	0.00198	CbGeAlD
Sorafenib—Vomiting—Metformin—polycystic ovary syndrome	0.000252	0.00857	CcSEcCtD
Sorafenib—Rash—Metformin—polycystic ovary syndrome	0.000249	0.0085	CcSEcCtD
Sorafenib—ABCG2—adrenal cortex—polycystic ovary syndrome	0.000249	0.00195	CbGeAlD
Sorafenib—Dermatitis—Metformin—polycystic ovary syndrome	0.000249	0.00849	CcSEcCtD
Sorafenib—Headache—Metformin—polycystic ovary syndrome	0.000248	0.00845	CcSEcCtD
Sorafenib—ABCC2—adrenal gland—polycystic ovary syndrome	0.000247	0.00193	CbGeAlD
Sorafenib—ABCC4—female gonad—polycystic ovary syndrome	0.000238	0.00186	CbGeAlD
Sorafenib—Nausea—Metformin—polycystic ovary syndrome	0.000235	0.00801	CcSEcCtD
Sorafenib—HTR2B—vagina—polycystic ovary syndrome	0.000235	0.00183	CbGeAlD
Sorafenib—CYP2B6—adrenal cortex—polycystic ovary syndrome	0.00023	0.00179	CbGeAlD
Sorafenib—CYP2C8—endometrium—polycystic ovary syndrome	0.000229	0.00179	CbGeAlD
Sorafenib—ABCG2—endometrium—polycystic ovary syndrome	0.000223	0.00174	CbGeAlD
Sorafenib—ABCC4—endocrine gland—polycystic ovary syndrome	0.000221	0.00173	CbGeAlD
Sorafenib—ABCC2—endocrine gland—polycystic ovary syndrome	0.000214	0.00167	CbGeAlD
Sorafenib—CYP2C8—pituitary gland—polycystic ovary syndrome	0.000207	0.00162	CbGeAlD
Sorafenib—ABCG2—uterus—polycystic ovary syndrome	0.000205	0.0016	CbGeAlD
Sorafenib—ABCG2—pituitary gland—polycystic ovary syndrome	0.000201	0.00157	CbGeAlD
Sorafenib—ABCG2—adipose tissue—polycystic ovary syndrome	0.000201	0.00157	CbGeAlD
Sorafenib—CYP2C19—vagina—polycystic ovary syndrome	0.000196	0.00153	CbGeAlD
Sorafenib—CYP3A5—adipose tissue—polycystic ovary syndrome	0.000186	0.00145	CbGeAlD
Sorafenib—CYP2C19—endocrine gland—polycystic ovary syndrome	0.000184	0.00144	CbGeAlD
Sorafenib—ABCG2—adrenal gland—polycystic ovary syndrome	0.00018	0.0014	CbGeAlD
Sorafenib—CYP2C8—vagina—polycystic ovary syndrome	0.000171	0.00134	CbGeAlD
Sorafenib—ABCG2—female gonad—polycystic ovary syndrome	0.000168	0.00131	CbGeAlD
Sorafenib—ABCG2—vagina—polycystic ovary syndrome	0.000167	0.0013	CbGeAlD
Sorafenib—CYP2B6—adrenal gland—polycystic ovary syndrome	0.000166	0.0013	CbGeAlD
Sorafenib—CYP2C8—endocrine gland—polycystic ovary syndrome	0.00016	0.00125	CbGeAlD
Sorafenib—CYP3A5—female gonad—polycystic ovary syndrome	0.000156	0.00122	CbGeAlD
Sorafenib—CYP3A5—vagina—polycystic ovary syndrome	0.000155	0.00121	CbGeAlD
Sorafenib—CYP2B6—vagina—polycystic ovary syndrome	0.000154	0.0012	CbGeAlD
Sorafenib—CYP1A2—endocrine gland—polycystic ovary syndrome	0.00015	0.00117	CbGeAlD
Sorafenib—ABCB1—embryo—polycystic ovary syndrome	0.00015	0.00117	CbGeAlD
Sorafenib—CYP3A5—endocrine gland—polycystic ovary syndrome	0.000145	0.00113	CbGeAlD
Sorafenib—CYP2B6—endocrine gland—polycystic ovary syndrome	0.000144	0.00112	CbGeAlD
Sorafenib—CYP2C9—endocrine gland—polycystic ovary syndrome	0.000143	0.00111	CbGeAlD
Sorafenib—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000123	0.000959	CbGeAlD
Sorafenib—CYP2D6—female gonad—polycystic ovary syndrome	0.000115	0.000898	CbGeAlD
Sorafenib—ABCB1—endometrium—polycystic ovary syndrome	0.00011	0.000857	CbGeAlD
Sorafenib—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000109	0.000848	CbGeAlD
Sorafenib—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000107	0.000835	CbGeAlD
Sorafenib—ABCB1—uterus—polycystic ovary syndrome	0.000101	0.000789	CbGeAlD
Sorafenib—ABCB1—pituitary gland—polycystic ovary syndrome	9.93e-05	0.000775	CbGeAlD
Sorafenib—ABCB1—adipose tissue—polycystic ovary syndrome	9.89e-05	0.000772	CbGeAlD
Sorafenib—ABCB1—adrenal gland—polycystic ovary syndrome	8.87e-05	0.000693	CbGeAlD
Sorafenib—ABCB1—female gonad—polycystic ovary syndrome	8.27e-05	0.000646	CbGeAlD
Sorafenib—ABCB1—vagina—polycystic ovary syndrome	8.22e-05	0.000642	CbGeAlD
Sorafenib—ABCB1—endocrine gland—polycystic ovary syndrome	7.69e-05	0.000601	CbGeAlD
Sorafenib—KIT—Signaling Pathways—POMC—polycystic ovary syndrome	3.04e-06	1.64e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	3.04e-06	1.64e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	3.03e-06	1.63e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	3.03e-06	1.63e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—INS—polycystic ovary syndrome	3.02e-06	1.63e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—INS—polycystic ovary syndrome	3.02e-06	1.63e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	3.02e-06	1.63e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—IL6—polycystic ovary syndrome	3.02e-06	1.63e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—LEP—polycystic ovary syndrome	3.01e-06	1.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—SERPINE1—polycystic ovary syndrome	3.01e-06	1.62e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—MTHFR—polycystic ovary syndrome	3.01e-06	1.62e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	3.01e-06	1.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—BCL2—polycystic ovary syndrome	3e-06	1.62e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.99e-06	1.61e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.99e-06	1.61e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—IL6—polycystic ovary syndrome	2.99e-06	1.61e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IRS1—polycystic ovary syndrome	2.98e-06	1.61e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—MTHFR—polycystic ovary syndrome	2.98e-06	1.61e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	2.98e-06	1.61e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	2.98e-06	1.6e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—GNAS—polycystic ovary syndrome	2.96e-06	1.59e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	2.94e-06	1.59e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IRS2—polycystic ovary syndrome	2.94e-06	1.58e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CYP19A1—polycystic ovary syndrome	2.94e-06	1.58e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	2.92e-06	1.58e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IGF1—polycystic ovary syndrome	2.92e-06	1.57e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IGF1—polycystic ovary syndrome	2.92e-06	1.57e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT2—polycystic ovary syndrome	2.92e-06	1.57e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT2—polycystic ovary syndrome	2.92e-06	1.57e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	2.9e-06	1.56e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	2.88e-06	1.55e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—POMC—polycystic ovary syndrome	2.88e-06	1.55e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PPARG—polycystic ovary syndrome	2.88e-06	1.55e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PPARG—polycystic ovary syndrome	2.88e-06	1.55e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—LEP—polycystic ovary syndrome	2.87e-06	1.55e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—POMC—polycystic ovary syndrome	2.87e-06	1.55e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CYP19A1—polycystic ovary syndrome	2.87e-06	1.55e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—INS—polycystic ovary syndrome	2.87e-06	1.54e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—INS—polycystic ovary syndrome	2.86e-06	1.54e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—IL6—polycystic ovary syndrome	2.86e-06	1.54e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	2.85e-06	1.54e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL6—polycystic ovary syndrome	2.84e-06	1.53e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—POMC—polycystic ovary syndrome	2.84e-06	1.53e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—POMC—polycystic ovary syndrome	2.84e-06	1.53e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—INS—polycystic ovary syndrome	2.82e-06	1.52e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—INS—polycystic ovary syndrome	2.82e-06	1.52e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.82e-06	1.52e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	2.81e-06	1.51e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	2.8e-06	1.51e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	2.78e-06	1.5e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	2.78e-06	1.5e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	2.77e-06	1.5e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.77e-06	1.49e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.77e-06	1.49e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.77e-06	1.49e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.77e-06	1.49e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.77e-06	1.49e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRG1—polycystic ovary syndrome	2.77e-06	1.49e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IGF1—polycystic ovary syndrome	2.76e-06	1.49e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT2—polycystic ovary syndrome	2.76e-06	1.49e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	2.75e-06	1.48e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IRS2—polycystic ovary syndrome	2.75e-06	1.48e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	2.74e-06	1.48e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.73e-06	1.47e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—TH—polycystic ovary syndrome	2.72e-06	1.46e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	2.7e-06	1.46e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IRS1—polycystic ovary syndrome	2.69e-06	1.45e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—LEP—polycystic ovary syndrome	2.69e-06	1.45e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—polycystic ovary syndrome	2.66e-06	1.44e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	2.65e-06	1.43e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	2.64e-06	1.43e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.63e-06	1.42e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.63e-06	1.42e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GNAS—polycystic ovary syndrome	2.62e-06	1.41e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	2.62e-06	1.41e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	2.6e-06	1.4e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—POMC—polycystic ovary syndrome	2.59e-06	1.4e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	2.58e-06	1.39e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	2.58e-06	1.39e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—INS—polycystic ovary syndrome	2.58e-06	1.39e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	2.57e-06	1.38e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IRS1—polycystic ovary syndrome	2.56e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	2.56e-06	1.38e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—polycystic ovary syndrome	2.56e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	2.56e-06	1.38e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.52e-06	1.36e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NCOR1—polycystic ovary syndrome	2.5e-06	1.35e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IGF1—polycystic ovary syndrome	2.49e-06	1.34e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT2—polycystic ovary syndrome	2.49e-06	1.34e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	2.49e-06	1.34e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	2.48e-06	1.33e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—POMC—polycystic ovary syndrome	2.47e-06	1.33e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.46e-06	1.33e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—INS—polycystic ovary syndrome	2.46e-06	1.32e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PPARG—polycystic ovary syndrome	2.44e-06	1.32e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	2.44e-06	1.32e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—TH—polycystic ovary syndrome	2.43e-06	1.31e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PPARG—polycystic ovary syndrome	2.42e-06	1.3e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—POMC—polycystic ovary syndrome	2.41e-06	1.3e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.4e-06	1.29e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—INS—polycystic ovary syndrome	2.39e-06	1.29e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—POMC—polycystic ovary syndrome	2.39e-06	1.29e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	2.38e-06	1.28e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IGF1—polycystic ovary syndrome	2.38e-06	1.28e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT2—polycystic ovary syndrome	2.37e-06	1.28e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—INS—polycystic ovary syndrome	2.37e-06	1.28e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IRS2—polycystic ovary syndrome	2.37e-06	1.28e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—TH—polycystic ovary syndrome	2.37e-06	1.28e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CYP1A1—polycystic ovary syndrome	2.37e-06	1.28e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.37e-06	1.28e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.37e-06	1.27e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	2.36e-06	1.27e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	2.35e-06	1.27e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	2.35e-06	1.27e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.33e-06	1.26e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—LEP—polycystic ovary syndrome	2.32e-06	1.25e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	2.31e-06	1.25e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—POMC—polycystic ovary syndrome	2.31e-06	1.24e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	2.3e-06	1.24e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	2.3e-06	1.24e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—INS—polycystic ovary syndrome	2.3e-06	1.24e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—polycystic ovary syndrome	2.26e-06	1.22e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.26e-06	1.22e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TH—polycystic ovary syndrome	2.23e-06	1.2e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	2.22e-06	1.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.22e-06	1.2e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	2.22e-06	1.2e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	2.22e-06	1.2e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	2.22e-06	1.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.22e-06	1.2e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TH—polycystic ovary syndrome	2.21e-06	1.19e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MTHFR—polycystic ovary syndrome	2.21e-06	1.19e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	2.18e-06	1.18e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	2.17e-06	1.17e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	2.17e-06	1.17e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	2.16e-06	1.16e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	2.15e-06	1.16e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.12e-06	1.14e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	2.11e-06	1.14e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.11e-06	1.14e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.1e-06	1.13e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—polycystic ovary syndrome	2.07e-06	1.12e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	2.07e-06	1.12e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	2.05e-06	1.1e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	2.04e-06	1.1e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—polycystic ovary syndrome	2.04e-06	1.1e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—polycystic ovary syndrome	2.04e-06	1.1e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	2.02e-06	1.09e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	2e-06	1.08e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	1.99e-06	1.07e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	1.98e-06	1.07e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	1.98e-06	1.07e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	1.98e-06	1.07e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—polycystic ovary syndrome	1.94e-06	1.04e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	1.93e-06	1.04e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—polycystic ovary syndrome	1.93e-06	1.04e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	1.92e-06	1.03e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	1.92e-06	1.03e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	1.91e-06	1.03e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.91e-06	1.03e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.91e-06	1.03e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TH—polycystic ovary syndrome	1.89e-06	1.02e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	1.89e-06	1.02e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—polycystic ovary syndrome	1.88e-06	1.02e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	1.87e-06	1.01e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	1.84e-06	9.93e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	1.84e-06	9.91e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	1.84e-06	9.9e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	1.82e-06	9.82e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.82e-06	9.81e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—polycystic ovary syndrome	1.82e-06	9.79e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	1.81e-06	9.78e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.81e-06	9.76e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	1.81e-06	9.73e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.81e-06	9.73e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—polycystic ovary syndrome	1.79e-06	9.64e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	1.79e-06	9.64e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—polycystic ovary syndrome	1.79e-06	9.64e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—polycystic ovary syndrome	1.78e-06	9.61e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—POMC—polycystic ovary syndrome	1.76e-06	9.51e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—INS—polycystic ovary syndrome	1.76e-06	9.46e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	1.75e-06	9.43e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—polycystic ovary syndrome	1.75e-06	9.41e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	1.75e-06	9.41e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—polycystic ovary syndrome	1.74e-06	9.38e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	1.74e-06	9.35e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	1.73e-06	9.32e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	1.72e-06	9.3e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	1.72e-06	9.27e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—INS—polycystic ovary syndrome	1.72e-06	9.25e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	1.71e-06	9.23e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—polycystic ovary syndrome	1.7e-06	9.17e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.7e-06	9.15e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	1.69e-06	9.09e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	1.67e-06	8.99e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	1.65e-06	8.87e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	1.63e-06	8.79e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	1.63e-06	8.77e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.63e-06	8.77e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—polycystic ovary syndrome	1.61e-06	8.66e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.55e-06	8.36e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—polycystic ovary syndrome	1.55e-06	8.36e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	1.54e-06	8.32e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	1.53e-06	8.27e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	1.52e-06	8.19e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	1.51e-06	8.16e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	1.49e-06	8.05e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—INS—polycystic ovary syndrome	1.49e-06	8.01e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	1.47e-06	7.92e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	1.47e-06	7.9e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—polycystic ovary syndrome	1.46e-06	7.89e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	1.46e-06	7.86e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.45e-06	7.82e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—polycystic ovary syndrome	1.45e-06	7.81e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—polycystic ovary syndrome	1.43e-06	7.72e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	1.42e-06	7.65e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	1.39e-06	7.51e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	1.35e-06	7.29e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	1.33e-06	7.19e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	1.33e-06	7.19e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—INS—polycystic ovary syndrome	1.33e-06	7.15e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	1.32e-06	7.11e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—polycystic ovary syndrome	1.32e-06	7.11e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—polycystic ovary syndrome	1.32e-06	7.11e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—POMC—polycystic ovary syndrome	1.3e-06	7.02e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	1.3e-06	7e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—INS—polycystic ovary syndrome	1.29e-06	6.98e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—polycystic ovary syndrome	1.25e-06	6.75e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.25e-06	6.75e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—polycystic ovary syndrome	1.25e-06	6.73e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	1.24e-06	6.7e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	1.23e-06	6.64e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	1.23e-06	6.61e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—INS—polycystic ovary syndrome	1.22e-06	6.57e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	1.22e-06	6.55e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—INS—polycystic ovary syndrome	1.21e-06	6.52e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	1.19e-06	6.42e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1.13e-06	6.12e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—polycystic ovary syndrome	1.13e-06	6.06e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	1.08e-06	5.8e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—polycystic ovary syndrome	1.07e-06	5.78e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	1.05e-06	5.68e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	1.04e-06	5.6e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—INS—polycystic ovary syndrome	1.03e-06	5.57e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—polycystic ovary syndrome	1e-06	5.41e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	1e-06	5.4e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	8.66e-07	4.67e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	8.13e-07	4.38e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	8.02e-07	4.32e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	7.98e-07	4.3e-06	CbGpPWpGaD
